このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Why Do People With Epilepsy Get More Infections? (Epi-IRIS)

2026年11月5日 更新者:University of Aberdeen

Epilepsy, Immune Dysfunction and Risk of Infection Study - A Prospective Cohort Study of Immune Dysfunction and Infection Risk With Epilepsy

People with epilepsy are predisposed to having seizures ("fits"), where abnormal electrical activity in the brain disrupts normal brain functioning. It is a common condition with around 1% of the population of Scotland having this condition. They are treated with anti-seizure medications, drugs which reduce the chance of having seizures.

Unfortunately, people with epilepsy are more likely to have severe infections than those without epilepsy and this is known to increase risk of seizures. The reasons for more severe infections in people with epilepsy are unclear, but one factor may be that anti-seizure medications impair the function of the body's immune system, which fights infection. The investigators' previous work looking at residents in the North-East of Scotland showed a link between these medications and risk of infection.

The investigators plan to study people being started on antiseizure medications (ASMs) with a new diagnosis of epilepsy and those already on ASMs with an established diagnosis of epilepsy in NHS Grampian. The investigators will compare with people not taking ASMs in a group of people with a single seizure and in a group of people with migraine.

The investigators will investigate immune function and infection risk with more-detailed information about individual's background, their seizures/epilepsy, other health conditions, and blood tests. The investigators will then do laboratory experiments to determine how ASMs may impair the immune system by looking at the function of types of white blood cells that play an important part in immune functioning.

The investigators also wish to develop statistical tools which can identify an individual's risk of infection when starting ASMs, based on their demographic, medical and social characteristics, to target closer monitoring/changes in treatment to those with higher risk.

This research will allow healthcare professionals to provide better individualised care in terms of which medication to use for treatment, what doses to use and whether blood tests to screen for impaired immune function would be helpful. The aim is that this will lead to reduced risk of infections in people with epilepsy, resulting in better outcomes in this condition.

調査の概要

詳細な説明

Background:

Epilepsy is a common neurological condition affecting 1% of the population and is associated with a 2.6-fold increased mortality risk, partly due to infection-related deaths. The investigators previously showed that anti-seizure medications (ASMs) are associated with abnormal immune function (hypogammaglobulinemia, lymphopenia, and neutropenia) and increased infection risk, but further work is needed to understand this risk and whether it can be reduced.

Aims:

  1. To clarify the effects of ASM on blood immune parameters
  2. To establish whether ASMs are associated with increased infection rates
  3. To explore potential mechanisms of immune dysfunction with commonly used ASMs
  4. To develop predictive models for infection risk based on clinical and laboratory data
  5. To develop and validate algorithms using routinely collected healthcare data to determine diagnosis of epilepsy, recurrence of seizure and good seizure control.

Protocol/methodology:

The investigators will recruit a cohort of approximately 500 participants: 100 new epilepsy cases and 100 established epilepsy cases (treated with ASMs) and 200-300 first seizures and 0-100 people with migraine (not treated with ASMs) and follow them for 10 years. This will result in an initial cohort of approximately 200 individuals treated with ASMs (new and established epilepsy) and 300 not treated with ASMs (between first seizure and migraine). Using this cohort, the investigators will investigate changes in immune parameters (hypogammaglobulinemia, lymphopenia, neutropenia) in people treated with ASMs. The investigators will then investigate the frequency of infections. These analyses will expand on the investigators' previous work by adjusting for co-morbidities and studying specific types of infection, such as opportunistic infections. The investigators will use routinely collected data to support the information gathered from patients during the study, and to validate the use of this for determining diagnosis of epilepsy and seizure frequency.

The investigators will investigate potential mechanisms of immune system dysfunction with ASMs with in vitro studies of innate immune system activity, including phagocytosis assays, killing assays, and viability assays in cultured macrophages/neutrophils with and without ASMs

The investigators will then develop a prognostic model to identify people taking ASMs who are at high risk of infection who may need monitoring of immune parameters.

Expected outcomes/benefits:

  1. A better understanding of infection risk in those treated with ASMs.
  2. Ability to identify those at high infection risk and intervene to reduce infection-related morbidity/mortality with screening, changing ASMs, or interventions directed at the mechanisms.

研究の種類

観察的

入学 (推定)

500

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

16年歳以上 (子、大人、高齢者)

健康ボランティアの受け入れ

なし

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Resident in an area covered by NHS Grampian neurology service.

Potential participants will have either been reviewed by the neurology team as an inpatient or outpatient.

説明

Inclusion Criteria:

  1. Adults aged 16 or over

  2. Resident in an area covered by NHS Grampian neurology service

  3. Individuals with:

    1. A diagnosis of first unprovoked (or reflex) seizure; or
    2. A new diagnosis of epilepsy (at least two unprovoked (or reflex) seizures occurring more than 24 hours apart)); or
    3. Established diagnosis of epilepsy; or
    4. A diagnosis of migraine
  4. Able to give informed consent to participate or, if lacking capacity, a reliable Welfare Guardian/Welfare Attorney/Nearest Relative can give consent on behalf of the participant.

Definition of established epilepsy in this context:

  1. The individual was diagnosed with epilepsy prior to the consultation at which the clinician referred them to the research team; or
  2. When a potential participant is identified from a previous clinic consultation, they already have a diagnosis of epilepsy.

Exclusion Criteria:

  1. Functional (non-epileptic) seizures without epileptic seizures or migraine. If the patient has both epileptic and functional seizures, or migraine and functional seizures, they would be eligible for inclusion, provided they meet the other criteria.

  2. Acute symptomatic seizure(s) without previous or subsequent unprovoked seizure(s) (e.g. due to head trauma, severe infection, significant electrolyte abnormality, alcohol withdrawal) would be an exclusion from the first seizure/epilepsy group.

  3. First seizure group:

    a) Those taking or are planned to be started on antiseizure medication(s)

  4. New diagnosis of epilepsy group:

    1. Those not planned to be started on an antiseizure medication
    2. Those taking, or are planned to be started on, two or more antiseizure medications
    3. Those already taking an antiseizure medication at the time of their new diagnosis of epilepsy
  5. Established epilepsy group:

    1. Those taking, or are planned to be started on, two or more antiseizure medications
    2. Those not taking an antiseizure medication, even if planned to be started on an antiseizure medication
  6. Migraine control group:

    1. Receiving treatment with antiseizure medications; or

    2. Receiving immunosuppressive* treatment for another condition; or

    3. Medical history of single unprovoked seizure or epilepsy

      • Exclusion due to immunosuppression increasing risk of immune dysfunction. Immunosuppression is not an exclusion criterion for first seizure/epilepsy groups as immunosuppression will be used as a variable for other analyses, including risk prediction analyses.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
介入・治療
Exposed

Individuals taking antiseizure medications

Antiseizure medications prescribed as routine care

他の名前:
  • Antiseizure medication
Unexposed

Individuals not taking antiseizure medications

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Infections
時間枠:During a 10 year period from the time of enrolment

Clinically significant rates of infection (community antimicrobial prescriptions or hospital admissions with infection)

During a 10 year period from the time of enrolment

二次結果の測定

結果測定
メジャーの説明
時間枠
Blood immune system parameters
時間枠:During a 10 year period from the time of enrolment

Abnormal level of blood immune system parameters (white blood cell counts, immunoglobulins, lymphocyte subsets)

During a 10 year period from the time of enrolment
Experimental laboratory tests
時間枠:Blood obtained during enrolment and/or 6 months after enrolment

In vitro macrophage and/or neutrophil functioning with exposure to common ASMs (carbamazepine, lamotrigine, levetiracetam, phenytoin, sodium valproate)

Blood obtained during enrolment and/or 6 months after enrolment
Prediction of infection
時間枠:During a 10 year period from the time of enrolment

A prognostic model (a statistical tool) that can be used to predict infection frequency in those being started on ASMs.

During a 10 year period from the time of enrolment
Validated algorithm
時間枠:During a 10 year period from the time of enrolment

Validated algorithms using routinely collected healthcare data to i) identify diagnoses of epilepsy; ii) measure seizure recurrence and iii) good seizure control.

During a 10 year period from the time of enrolment

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年11月4日

一次修了 (推定)

2038年5月1日

研究の完了 (推定)

2038年5月1日

試験登録日

最初に提出

2026年10月21日

QC基準を満たした最初の提出物

2026年10月21日

最初の投稿 (実際)

2026年10月29日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月10日

QC基準を満たした最後の更新が送信されました

2026年11月5日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 26/SS/0081-IRAS-367495
  • GCA25219 (その他の助成金/資金番号:NHS Grampian Charities)
  • 2-006-26 (その他の識別子:University of Aberdeen - Sponsor Reference Number)

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する